Launch of Deferiprone Tablets USP - Senores Pharmaceuticals Ltd

Code BSE: 544319 NSE:

Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg which will be marketed by Dr. Reddy’s Laboratories Inc. in the US market “We are pleased to advance our growth with the launch of a limited-competition product. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited. Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025 according to symphony.